获得性血管性血友病综合征的临床与实验室特征
单中心回顾性横断面研究纳入2014年4月至2025年3月确诊的140例获得性血管性血友病综合征(AVWS)患者,其中76%为骨髓增殖性肿瘤(MPN)、19%为淋巴增殖性疾病(LPD)。LPD以严重VWF功能缺陷、高分子量多聚体(HMWM)显著丢失及VWFpp/VWF:Ag比值升高(中位6.7)为特征,提示清除加速;MPN则表现为轻度HMWM减少、清除正常(中位比值1.0)。LPD临床相关出血(58%)比MPN(13%)更常见且更严重。
要点
- AVWS主要继发于MPN(76%)和LPD(19%),两类疾病出血表型与机制不同。
- LPD呈免疫介导表型:VWF功能严重缺陷、HMWM显著丢失、VWFpp/VWF:Ag比值升高提示清除加速。
- MPN呈血小板介导表型:HMWM轻度减少、清除正常,血小板计数与HMWM缺失程度呈负相关(ρ=-0.48,p<0.001)。
核心结论
- AVWS在LPD中为免疫介导表型、在MPN中为血小板介导表型,明确机制对精准诊断和靶向治疗、降低出血风险至关重要。
研究设计与样本
- 单中心、回顾性横断面研究,纳入2014年4月至2025年3月在Angelo Bianchi Bonomi血友病与血栓中心确诊的AVWS患者140例。
- 出血严重程度采用ISTH-BAT评分评估。
- 实验室检测包括FVIII:C、VWF:Ag、VWF:GPIbR、VWF:RCo、VWF:CB、VWFpp及多聚体分析。
主要发现
- 140例中106例(76%)为MPN,26例(19%)为LPD。
- 70%患者至少有一种出血症状,24%发生临床显著出血。
- 临床相关出血(主要为皮肤黏膜和胃肠道)在LPD中更常见更严重(58%),高于MPN(13%)。
- LPD显示严重VWF功能缺陷、显著HMWM丢失及VWFpp/VWF:Ag比值升高(中位6.7),符合清除加速。
- MPN显示轻度HMWM减少、清除正常(中位VWFpp/VWF:Ag比值1.0),血小板计数与HMWM缺失程度呈负相关(ρ=-0.48,p<0.001)。
关键数值与推荐
- LPD中VWFpp/VWF:Ag比值中位6.7,MPN中位1.0。
- MPN中血小板计数与HMWM缺失程度负相关(ρ=-0.48,p<0.001)。
- LPD中出血严重程度与VWF:GPIbR负相关(ρ=-0.50,p=0.02)。
- 受检LPD或自身免疫病例中抗VWF抗体阳性率30%。
临床怎么用
- 对MPN或LPD患者出现出血表现时应考虑AVWS,并行VWF功能、多聚体及VWFpp/VWF:Ag比值检测。
- VWFpp/VWF:Ag比值升高提示清除加速,支持LPD相关免疫介导机制。
- 依据LPD(免疫介导)与MPN(血小板介导)的不同机制选择针对性治疗以降低出血风险。
局限性
- 单中心、回顾性、横断面设计,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acquired von Willebrand Syndrome (AVWS) is a rare bleeding disorder characterized by quantitative or qualitative defects of von Willebrand factor (VWF) in patients without a personal or family history of bleeding. It is frequently associated with systemic diseases, particularly lymphoproliferative disorders (LPDs) and myeloproliferative neoplasms (MPNs). In this single-center, retrospective cross-sectional study, we included patients diagnosed with AVWS at the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center between April 2014 and March 2025. Bleeding severity was assessed using the ISTH-BAT score. Laboratory tests included FVIII:C, VWF:Ag, VWF:GPIbR, VWF:RCo, VWF:CB, VWFpp, and multimer analysis. Among 140 patients, 106 (76%) had MPNs and 26 (19%) LPDs. At least one bleeding symptom was observed in 70% of patients, with clinically significant bleeding occurring in 24% of the cohort. Clinically relevant bleeding (mainly mucocutaneous and gastrointestinal) was more frequent and severe in LPDs (58%) than in MPNs (13%). LPDs showed severe VWF functional defects, marked HMWM loss, and elevated VWFpp/VWF:Ag ratios (median 6.7), consistent with accelerated clearance. MPNs displayed mild HMWM reduction, normal clearance (median VWFpp/VWF:Ag ratio 1.0), and an inverse correlation between platelet count and the degree of HMWM depletion (ρ = -0.48, p < 0.001). Bleeding severity correlated inversely with VWF:GPIbR in LPDs (ρ = -0.50, p = 0.02) and with VWF:RCo in MPNs. Anti-VWF antibodies were found in 30% of tested LPDs or autoimmune cases. The two main phenotypes presented in AVWS were immune-mediated in LPDs and platelet-mediated in MPNs. Understanding the underlying mechanism is crucial for accurate diagnosis and targeted treatment to reduce bleeding risk and improve outcomes.
引用
- Ciavarella A, Baronciani L, Seidizadeh O, et al. Clinical and Laboratory Characterization of Acquired Von Willebrand Syndrome. Am J Hematol. 2026. PMID: 42272198. doi:10.1002/ajh.70399
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。